Following two weeks of cerebroventricular administration of arginine-vasopressin (AVP) by Accurel implants, two types of binding sites for this peptide were immunocytochemically visualized in blood vessels in the brain of Brattleboro (di/di) rats: (1) endothelial cells of capillaries were stained with the highest density in hippocampus, striatum, and locus coeruleus (LC), whereas only few such stained cells were present in the septum and cerebral cortex. (2) Bound AVP was also present on endothelial cells and pericyte-like cells in larger blood vessels in striatum and the LC. Both types of vasopressin binding site staining on blood vessels were dose-dependent and could be further enhanced by additional in vitro preincubation of the fixed sections with AVP. This staining was not present in rats implanted with either oxytocin or a-melanocyte-stimulating hormone.
An effect of arginine-vasopressin (AVP) on the permeability of the blood-brain barrier (BBB) has been reported for transport of various nutrient substances 3'4'19'26. In addition, AVP is known to affect water permeability of brain microvessels 7,22,27. Binding assays have shown the presence of binding sites on isolated brain microvessels sA3,15,16,2°. Most studies concerning binding sites in the vascular bed of the brain were performed with homogenate binding assays or receptor autoradiography, which has a low resolution. Therefore, morphological localization of these binding sites in situ has not been reported so far.
In the present study, a recently introduced immunocytochemical (ICC) procedure has been applied for the localization of AVP binding sites in the vascular bed of the brain. This procedure was developed for visualizing peptidergic binding sites in the rat kidney and brain with a higher resolution than autoradiographic techniques 23,24,25 and is based upon continuous intracerebroventricular administration of peptides, using Accurel polymer tubing filled with a ligand 237. The ligand is subsequently immunocytochemically stained in fixed tissue.
Male Brattleboro rats, 3 months of age and homozygous for diabetes insipidus (di/di), were obtained from the Central Animal Supply House, CPB-TNO (Zeist, the Netherlands). These vasopressin-deflcient rats were chosen in order to avoid cross-reactive immunostaining of the antisera with endogenous AVP, as we have reported earlier 23,z4.
Unilateral implants of AVP/Accurel in the lateral ventricle contained either 0.15, 1.5 or 15/~g of AVP (n = 7) or water-filled tubing (n = 5). In addition, 6 rats were implanted with 15/tg oxytocin (OXT) and 5 with a-melanocyte-stimulating hormone (a-MSH) filled Accurel tubing. The following preparations of peptides were used: AVP (Sigma, St. Louis, MO, grade VIII, 358 IU/mg); OXT (Sigma, St. Louis, MO, grade X, 540 IU/mg); a-MSH (WB 1138 K1, kindly donated by Dr. H. Greven, Organon, The Netherlands). Two weeks later, the rats were perfused intracardially with 2.5% glutaraldehyde and 1% paraformaldehyde. Transverse free-floating vibra- 
